Submitted by Verena Bastos (verena@uefs.br) on 2015-08-05T22:08:06Z No. of bitstreams: 1 Disserta??o Mona Oliveira vers?o final Maio2003 PPGbiotec.pdf: 4793209 bytes, checksum: 5e62150796f4527c8d492f92de5041e2 (MD5) / Made available in DSpace on 2015-08-05T22:08:06Z (GMT). No. of bitstreams: 1 Disserta??o Mona Oliveira vers?o final Maio2003 PPGbiotec.pdf: 4793209 bytes, checksum: 5e62150796f4527c8d492f92de5041e2 (MD5) Previous issue date: 2013-05-08 / Funda??o de Amparo ? Pesquisa do Estado da Bahia - FAPEB / Glioblastomas (GBMs) are the most common and aggressive primary tumors of the CNS. The survival of patients with this diagnosis remains very low, with poor prognosis even after surgical therapy associated with radiotherapy and chemotherapy. The present work carried out a screening for 24 synthetic ?alkaloid-like? to determine their effects on cell viability of quimioresistentes human (Gl-15 and U251) glioblastoma cells and murine (C6) glioma cells. Among the alkaloids tested (100?M) RLB87 was the most cytotoxic for transformed cells, inhibiting the viability in 75.0% 97.2% 76.6% of GL-15, U251 and C6 cells, respectively, after 72 h exposure, and it did not show toxicity to normal glial cells. It was also observed that RLB87 promoted apoptosis, 24 and 72 h after treatment, in a time-dependent manner. Moreover RLB87 also inhibited cell migration and proliferation with cells arrest at G0/G1 phase, since 24 h after treatment. Additionally, the cytotoxicity of four RLB87 analogues was tested in view to elucidate important aspects in chemical structure, required for its activity. We observed positive correlation between cytotoxic effect and isomeric of phenyl functions, with ester function and also lipophilicity. These finding suggest the ?alkaloid-like? RLB87 as a promising anticancer agent as well as a prototype for new agents for treatment of malignant and recurrent gliomas. / Glioblastomas (GBMs) s?o os tumores prim?rios mais comuns e agressivos do SNC. A sobrevida dos pacientes com esse diagn?stico continua muito baixa, tendo progn?stico ruim mesmo ap?s terapia cir?rgica seguida de radio e quimioterapia. No presente trabalho, foi realizada a prospec??o de 24 mol?culas de s?ntese, alkaloids-like, para determina??o de seus efeitos sobre a viabilidade de c?lulas quimioresistentes de glioblastoma humano (GL-15 e U251) e murina (C6). Entre os compostos testados ? (100JM), RLB87 foi o mais citot?xico para c?lulas transformadas, inibindo a viabilidade em 75,0%, 97,2%, 76,6% da GL-15, U251 e C6, respectivamente e o mesmo n?o apresentou toxicidade para c?lulas gliais normais. Observou-se, que o RLB87 promoveu apoptose 24 e 72 h ap?s o tratamento de forma tempo-dependente. O RLB87 igualmente inibiu a prolifera??o celular com acumulo na fase G0/G1 do ciclo celular ap?s 24 h. A migra??o das c?lulas de glioma foi tamb?m inibida ap?s tratamento com RLB87. Adicionalmente 4 an?logos do RLB87 foram tamb?m avaliados, elucidando aspectos importantes na estrutura qu?mica, requeridos para sua atividade, que possuem correla??o positiva com regioisomeria das fenilas, presen?a da fun??o ?ster e lipofilicidade. O RLB87 ? apresentado como promissor agente antineopl?sico assim como um prot?tipo para novos agentes terap?uticos para o tratamento de gliomas malignos e recidivados.